Compare WTBA & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WTBA | EVO |
|---|---|---|
| Founded | 1893 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 488.6M | 568.6M |
| IPO Year | 2002 | 2007 |
| Metric | WTBA | EVO |
|---|---|---|
| Price | $28.67 | $1.55 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $24.00 | $7.00 |
| AVG Volume (30 Days) | 36.3K | ★ 138.4K |
| Earning Date | 04-23-2026 | 04-08-2026 |
| Dividend Yield | ★ 4.17% | N/A |
| EPS Growth | ★ 35.21 | N/A |
| EPS | ★ 1.26 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.80 | $1.37 |
| Revenue Next Year | $9.39 | $10.05 |
| P/E Ratio | $23.18 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.03 | $1.50 |
| 52 Week High | $30.33 | $4.27 |
| Indicator | WTBA | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 53.55 | N/A |
| Support Level | $27.54 | N/A |
| Resistance Level | $30.12 | N/A |
| Average True Range (ATR) | 0.48 | 0.00 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 38.04 | 0.00 |
West Bancorp Inc is a United States-based company that offers a full range of deposit services, including checking, savings, and money market accounts and time certificates of deposit. West Bank also offers online banking, mobile banking, and treasury management services, which help to meet the banking needs of its customers. Treasury management services offered to business customers include cash management, client-generated automated clearing house transactions, remote deposit, and fraud protection services. Also offered are merchant credit card processing and corporate credit cards. The bank operates only in the United States of America.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.